Gareth Morgan Investments Limited Partnership cut its stake in Allergan PLC. (NYSE:AGN) by 49.2% in the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 21,270 shares of the company’s stock after selling 20,621 shares during the period. Gareth Morgan Investments Limited Partnership’s holdings in Allergan PLC. were worth $5,171,000 as of its most recent SEC filing.

A number of other large investors also recently made changes to their positions in the stock. Veritas Asset Management LLP purchased a new stake in Allergan PLC. during the first quarter valued at about $761,339,000. Iridian Asset Management LLC CT boosted its position in Allergan PLC. by 141.3% during the first quarter. Iridian Asset Management LLC CT now owns 1,283,833 shares of the company’s stock valued at $306,733,000 after buying an additional 751,848 shares during the period. Renaissance Technologies LLC purchased a new stake in Allergan PLC. during the first quarter valued at about $124,255,000. Blue Ridge Capital L.L.C. boosted its position in Allergan PLC. by 24.1% during the first quarter. Blue Ridge Capital L.L.C. now owns 1,909,900 shares of the company’s stock valued at $456,313,000 after buying an additional 370,400 shares during the period. Finally, Harbour Capital Advisors LLC boosted its position in Allergan PLC. by 21,412.3% during the second quarter. Harbour Capital Advisors LLC now owns 345,917 shares of the company’s stock valued at $1,423,000 after buying an additional 344,309 shares during the period. Institutional investors own 82.02% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This report was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this report on another publication, it was copied illegally and reposted in violation of international copyright & trademark legislation. The original version of this report can be read at https://www.thecerbatgem.com/2017/09/25/gareth-morgan-investments-limited-partnership-cuts-position-in-allergan-plc-agn.html.

Several research firms have issued reports on AGN. Mizuho restated a “buy” rating and set a $267.00 price target on shares of Allergan PLC. in a research report on Wednesday, August 2nd. Royal Bank Of Canada set a $285.00 price target on shares of Allergan PLC. and gave the company a “buy” rating in a research report on Thursday, August 3rd. Wells Fargo & Company upped their price target on shares of Allergan PLC. to $278.00 and gave the company an “outperform” rating in a research report on Thursday, August 3rd. Deutsche Bank AG restated a “buy” rating and set a $273.00 price target (up from $265.00) on shares of Allergan PLC. in a research report on Monday, July 17th. Finally, BidaskClub upgraded shares of Allergan PLC. from a “hold” rating to a “buy” rating in a research report on Saturday, June 24th. One research analyst has rated the stock with a sell rating, eight have given a hold rating and fourteen have assigned a buy rating to the company. Allergan PLC. currently has a consensus rating of “Buy” and a consensus price target of $273.34.

Allergan PLC. (NYSE:AGN) opened at 204.65 on Monday. Allergan PLC. has a 1-year low of $184.50 and a 1-year high of $256.80. The company has a 50-day moving average of $229.79 and a 200-day moving average of $236.07. The company has a market capitalization of $68.42 billion, a P/E ratio of 6.24 and a beta of 1.18.

Allergan PLC. (NYSE:AGN) last released its quarterly earnings data on Thursday, August 3rd. The company reported $4.02 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.95 by $0.07. The company had revenue of $4.01 billion during the quarter, compared to analysts’ expectations of $3.95 billion. Allergan PLC. had a net margin of 79.17% and a return on equity of 7.37%. The firm’s quarterly revenue was up 8.8% on a year-over-year basis. During the same period in the previous year, the company earned $3.35 EPS. Equities analysts expect that Allergan PLC. will post $16.26 EPS for the current fiscal year.

The business also recently disclosed a quarterly dividend, which was paid on Friday, September 15th. Shareholders of record on Friday, August 18th were given a $0.70 dividend. The ex-dividend date was Wednesday, August 16th. This represents a $2.80 annualized dividend and a yield of 1.37%. Allergan PLC.’s dividend payout ratio (DPR) is 9.95%.

Allergan PLC. Profile

Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.

Want to see what other hedge funds are holding AGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allergan PLC. (NYSE:AGN).

Institutional Ownership by Quarter for Allergan PLC. (NYSE:AGN)

Receive News & Stock Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related stocks with our FREE daily email newsletter.